Merck KGaA, Bristol-Myers Squibb Company, and Glycostem are Dominating the Global Natural Killer (NK) Cell Therapeutics Market in 2019

Global Natural Killer (NK) Cell Therapeutics Market is expected to grow with the CAGR of 40.5% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report @

Global natural killer (NK) cell therapeutics market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global natural killer (NK) cell therapeutics market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

  • In June 2020, Merck KGaA received FDA approval for BAVENCIO, a PD-L1 targeted NK –cell therapy used for treatment of locally advanced urothelial carcinoma. This FDA approval helped the company to enhance its product portfolio which led it to earn more revenue.

Merck KGaA is the dominating player in the global natural killer (NK) cell therapeutics market. The other key players existing in the market are Kiadis Pharma, Cytovia Therapeutics, Nkarta, Inc., Fate Therapeutics, EMERcell, Glycostem, Phio Pharmaceuticals, Innate Pharma, Inc., INmuneBIO, Gamida Cell, Bellicum Phamaceuticals, Inc., Acepodia Inc., Affimed GmbH, multimmune GmbH, Bristol-Myers Squibb Company, Kleo Pharmaceuticals, iCell Gene Therapeutics, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., NantKwest among others.

Natural Killer (NK) Cell Therapeutics Market Merck KGaA

Merck KGaA headquartered is in Darmstadt, Germany. The company is engaged in providing solutions in the field of healthcare, life science and performance materials with a passion for technology and love for science. The company has three business segments including life science, healthcare, performance materials, in which healthcare is the market focused segment. The company has wide product categories such as healthcare, life science, performance materials in which healthcare is the market focused category. The company has wide presence across Africa, Asia, Europe, Latin America, North America, Oceania. The company also has various subsidiary companies such as Sigma-Aldrich (OM) Ltd. (Greece), Merck Foundation gGmbH (Germany), Merck S.A. (Venezuela), iOnctura SA (Switzerland), Merck Ltd. (U.K), Fluka Chemical Corp. (U.S.), among others.

For instance,

  • In October 2019, Merck KGaA received European Commission approval for BAVENCIO to for treatment of advanced renal cell carcinoma (RCC). This approval enhanced the company’s product portfolio for NK cell therapy and allowed it to generate more revenue.

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is headquartered in New York, U.S. founded in the 1887. The company is engaged in discovery, development and delivery of transformational medicines in different areas involving oncology, immunoscience, cardiovascular and fibrosis. The company has wide pipeline product categories which are solid tumors, hematology, immunology, fibrotic diseases, cardiovascular, neuroscience in which solid tumors, hematology, immunology are the market focused categories. The company has presence across North America, Europe, and Asia-Pacific. The company has various subsidiaries such as Ability Biomedical (USA) Corp.(U.S.), Bristol-Myers Squibb Canada Co.(Canada), Bristol-Myers Squibb Argentina S. R. L.(Argentina), BMS Pharmaceuticals Germany Holdings , B.V.(Germany), BMS Spain Investments, Inc.(Spain) among others.

For instance,

  • In August 2020, Bristol-Myers Squibb Company received positive result from phase 3 clinical trial of Opdivo (nivolumab) administered for treatment of disease arising after the resection of esophageal or gastroesophageal junction cancer. The Opdivo (nivolumab) is a NK cell based therapy and hence this result paved the way for the company to get product approval and to put its footprint in NK cell therapeutic market.


Glycostem headquartered in Oss, the Netherlands. The company is focused on the development of stem cells derived natural - killer cells as a medicinal asset in the fight against cancer. The company has three pipeline products oNKord, CAR-NK, TCR-NK, which all are market focused products. The company has presence in Europe.

For instance,

  • In November 2019, Glycostem signed partnership agreement with Zelluna immunotherapy, a company focused on the development of adoptive cell therapies and products for treatment of solid tumors. As Glycostem is a clinical stage company, this partnership helped it to fasten the development of its NK cell therapeutic products.